Advancing the Development and Accessibility of Vaccines Against Bacterial and Viral Pathogens in Low- and Middle-Income Countries (LMICs)
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines and Public Health".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 53
Special Issue Editors
Interests: microbiology; viruses; antivirals; vaccines; innate immunity; adaptive immunity; vaccine development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In light of ongoing global health disparities, there is a critical need to advance research into vaccines that are specifically tailored for low- and middle-income countries (LMICs) in order to promote equitable health outcomes. This Special Issue seeks to highlight innovative research and practical solutions led by researchers from low- and middle-income countries (LMICs) to address vaccine development challenges, with a particular focus on multidrug-resistant pathogens and context-specific vaccine delivery. We welcome studies employing cutting-edge technologies such as artificial intelligence, case studies on overcoming vaccine distribution barriers, and efforts to correct epistemic injustice by amplifying the voices of researchers from LMICs. Our goal is to provide a focused platform that drives innovation in the development of vaccines tailored to the unique needs and constraints of LMIC settings.
We look forward to your contributions to the advancement of equitable vaccine research and the improvement of global health.
Dr. Ahmed Mostafa
Dr. Sherif Abouelhadid
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- LMICs
- infection
- bacterial
- AMR
- viral
- pandemic
- epidemic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
